Xencor (XNCR) Debt Ratio (2023 - 2026)

Xencor (XNCR) posted quarterly Debt Ratio of 0.15 for Q1 2026, down 13.68% year-over-year from 0.17 in Q1 2025, and up 7.69% quarter-over-quarter from 0.14 in Q4 2025.

Xencor (XNCR) Debt Ratio (2023 - 2026) Analysis & Trends

Xencor (XNCR) has reported Debt Ratio for 4 consecutive years, with 0.15 the latest figure, recorded in Q1 2026.

  • In Q1 2026, Debt Ratio fell 13.68% year-over-year to 0.15; the TTM figure through Mar 2026 stood at 0.15 (down 13.68% YoY), while the FY2025 annual figure was 0.14, down 20.42% from the prior year.
  • Debt Ratio rose to 0.15 in Q1 2026 per XNCR's latest filing, from 0.14 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.21 in Q2 2024 and bottomed at 0.14 in Q4 2025.
  • Historically, Debt Ratio has averaged 0.17 across 4 years, with a median of 0.17 in 2024.
  • On a YoY basis, Debt Ratio climbed as much as 11.32% in 2025 and fell as far as 22.88% in 2025.
  • Xencor's Debt Ratio stood at 0.2 in 2023, then fell by 12.46% to 0.17 in 2024, then slipped by 20.42% to 0.14 in 2025, then gained by 7.69% to 0.15 in 2026.
  • Business Quant data shows XNCR's Debt Ratio at 0.15 in Q1 2026, 0.14 in Q4 2025, and 0.15 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.05
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 0.12
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 0.47
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 0.26
10 Xencor 1.73 Bn 1.36 Bn - 0.14

Historic Data

Download Data
DateValue
Jun 30, 2026 0.14
Mar 31, 2026 0.15
Dec 31, 2025 0.14
Sep 30, 2025 0.15
Jun 30, 2025 0.16
Mar 31, 2025 0.17
Dec 31, 2024 0.17
Sep 30, 2024 0.17
Jun 30, 2024 0.21
Mar 31, 2024 0.21
Dec 31, 2023 0.20